Nanobiotechnology: traditional re-interpreting personalized medicine through targeted therapies and regenerative...

Nanobiotechnology is transforming personalized medicine by leveraging the unique properties of nanomaterials to address key challenges in targeted drug delivery, regenerative medicine, and diagnostics. The development of nanocarriers, such as liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, has enabled precise drug delivery with enhanced bioavailability and reduced systemic toxicity. Concurrently, nanostructured scaffolds have advanced regenerative medicine by supporting stem cell differentiation, modulating cellular microenvironments, and enhancing tissue repair. These nanoscale innovations have also led to highly sensitive biosensors and imaging agents, significantly improving early disease detection and biomarker monitoring. Despite these advancements, challenges persist, including nanoparticle-induced cytotoxicity, immunogenicity, scalability issues, and regulatory hurdles requiring extensive evaluation of long-term biocompatibility and pharmacokinetics. Addressing these limitations, recent breakthroughs in AI-assisted nanotechnology and CRISPR-Cas9-mediated gene editing are driving next-generation precision medicine, integrating nanoscale therapeutics with computational approaches to enhance efficacy. Future directions focus on nanorobotics, bioengineered nanovaccines, and theranostic platforms capable of simultaneous diagnosis and treatment, paving the way for real-time, patient-specific interventions. The successful translation of nanomedicine into clinical practice will require interdisciplinary collaboration across nanoscience, bioengineering, and translational medicine to refine nanoparticle functionalization, optimize safety profiles, and ensure equitable access to nanotherapeutics. This review provides a comprehensive overview of these advancements, challenges, and emerging opportunities in nanobiotechnology-driven precision medicine.